[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370807-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370807-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-of-zhpv16e7-granzyme-b-immunoaftoxin-dual-mechanisms-targeting-hpv16-positive-cervical-cancer-through-epithelial-mesenchymal-transition-inhibition-and-cell-death","Development of ZHPV16E7-granzyme B immunoafﬁtoxin - dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death","","A novel immunotoxin, ZHPV16E7-GrB, was engineered by fusing an HPV16E7-specific afﬁbody with the cytotoxic effector granzyme B to target HPV16-positive cervical cancer. The study assessed binding specificity across HPV16/HPV18-positive and HPV-negative cell lines and evaluated anti-tumor activity via viability, migration, EMT marker modulation, apoptosis assays, and pyroptosis readouts. Results showed inhibited growth and suppressed EMT, alongside caspase-dependent apoptosis and GSDME-mediated pyroptosis with selective cytotoxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-of-zhpv16e7-granzyme-b-immunoaftoxin-dual-mechanisms-targeting-hpv16-positive-cervical-cancer-through-epithelial-mesenchymal-transition-inhibition-and-cell-death/370807/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-of-zhpv16e7-granzyme-b-immunoaftoxin-dual-mechanisms-targeting-hpv16-positive-cervical-cancer-through-epithelial-mesenchymal-transition-inhibition-and-cell-death/370807.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was ZHPV16E7-GrB designed and what target does it recognize?","Question",{"text":63,"@type":64},"ZHPV16E7-GrB was engineered by fusing an HPV16E7-specific afﬁbody (ZHPV16E7) with granzyme B. It is designed to precisely target HPV16-positive cervical cancer cells expressing HPV16E7.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which experiments were used to evaluate binding specificity and anti-cancer activity?",{"text":68,"@type":64},"Binding specificity was assessed by ELISA and immunofluorescence using HPV16/HPV18-positive and HPV-negative cervical cancer cell lines. Anti-cancer effects were measured with cell viability assays, migration assays (Transwell), EMT marker detection (Western blot), and cell death assays.",{"name":70,"@type":61,"acceptedAnswer":71},"What dual mechanisms did ZHPV16E7-GrB activate in HPV16-positive cells?",{"text":72,"@type":64},"ZHPV16E7-GrB inhibited EMT by reducing migration and invasion and modulating EMT markers. It also induced apoptosis through caspase-3/caspase-8 activation and triggered pyroptosis via direct cleavage of GSDME, producing membrane rupture and pro-inflammatory cytokine release.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370807,1790722437,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Original Research PUBLISHED 21 July 2025  \nDOI 10.3389/fimmu.2025.1616715  \nOPEN ACCESS  \nEDITED BY  \nMichal Amit Rahat,  \nTechnion-Israel Institute of Technology, Israel  \nREVIEWED BY  \nDipendra Khadka,  \nWonkwang University, Republic of Korea Haijun Wang,  \nShandong First Medical University, China  \n*CORRESPONDENCE  \nWenshu Li  \n [lwswz2019@163.com](lwswz2019@163.com)[ ](lwswz2019@163.com)Lifang Zhang  \n [lifangzhangwz@126.com](lifangzhangwz@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 17 May 2025  \nACCEPTED 02 July 2025  \nPUBLISHED 21 July 2025  \nCITATION  \nTan X, Yang J, Li Y, Wan K, Feng S, Jing X, Xie Z, Zhang L and Li W (2025)  \nDevelopment of ZHPV16E7-granzyme Bimmunoafﬁtoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death.  \nFront. Immunol. 16:1616715 .  \ndoi: 10.3389/fimmu.2025.1616715  \nCOPYRIGHT  \n© 2025 Tan, Yang, Li, Wan, Feng, Jing, Xie, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDevelopment of ZHPV16E7-granzyme B immunoafﬁtoxin:  \ndual mechanisms targeting hpv16-positive cervical cancer through epithelialmesenchymal transition inhibition and cell death  \nXiaochun Tan 1,2†, Jiani Yang 1,3†, Yanheng Li 1, Kairong Wan 1, Sicong Feng 1, Xishang Jing 1, Zhenyun Xie 4,  \nLifang Zhang 1* and Wenshu Li 1*  \n1 Institute of Molecular Virology and Immunology, Department of Microbiology & Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China, 2 Department of Laboratory  \nMedicine, The First Hospital of Jiaxing, Afﬁliated Hospital of Jiaxing University, Jiaxing, China, 3 Department of Laboratory Medicine, Nanjing University of Chinese Medicine, Yancheng TCM Hospital, Yancheng, China, 4Communication Department, Technical University of Valencia, Valencia, Spain  \nIntroduction: Cervical cancer, predominantly caused by high-risk human papillomavirus (HPV), remains a major global health challenge. HPV16 is the most prevalent type, and its oncoprotein E7 promotes epithelial-mesenchymal transition (EMT), a critical step in metastasis. Current therapies for HPV16-related cancers are often insufﬁcient, highlighting the need for targeted treatments. We engineered a novel immunotoxin, ZHPV16E7-GrB, by fusing an HPV16E7-speciﬁc afﬁbody (ZHPV16E7) with the cytotoxic immune effector granzyme B (GrB) . This construct was designed for precise targeting and therapeutic activity against HPV16-positive cervical cancer cells.  \nMethods: ZHPV16E7-GrB was engineered, expressed in E. coli, and puriﬁed. Binding speciﬁcity was assessed via ELISA and immunoﬂuorescence using HPV16-positive (SiHa, CaSki), HPV18-positive (HeLa), and HPV-negative (C33A) cervical cancer cells. Functional assays evaluated cell viability (LDH release, luminescence), migration (Transwell), EMT markers (Western blot for Ecadherin, N-cadherin, Vimentin, Snail), apoptosis (TUNEL, ﬂow cytometry, caspase activation), and pyroptosis (SYTOX Green uptake, cytokine release ELISA, GSDME cleavage) . Caspase-3 knockdown and in vitro cleavage assays determined pyroptosis mechanisms.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nResults: ZHPV16E7-GrB exhibited strong binding speciﬁcity for HPV16E7 . It signiﬁcantly inhibited cell growth and suppressed EMT in HPV16-positive cells, evidenced by reduced migration and invasion, downregulation of Vimentin and Snail, increased E-cadherin, and decreased N-cadherin expression. Furthermore, ZHPV16E7-GrB induced apoptosis via caspase-3/caspase-8 activation and trigger","cbCaijOhiKv2EhtG","https://ap.wps.com/l/cbCaijOhiKv2EhtG","pdf",13665918,17,"English","# Introduction\n## Methods\n## Results\n## Discussion","[{\"question\":\"How was ZHPV16E7-GrB designed and what target does it recognize?\",\"answer\":\"ZHPV16E7-GrB was engineered by fusing an HPV16E7-specific afﬁbody (ZHPV16E7) with granzyme B. It is designed to precisely target HPV16-positive cervical cancer cells expressing HPV16E7.\"},{\"question\":\"Which experiments were used to evaluate binding specificity and anti-cancer activity?\",\"answer\":\"Binding specificity was assessed by ELISA and immunofluorescence using HPV16/HPV18-positive and HPV-negative cervical cancer cell lines. Anti-cancer effects were measured with cell viability assays, migration assays (Transwell), EMT marker detection (Western blot), and cell death assays.\"},{\"question\":\"What dual mechanisms did ZHPV16E7-GrB activate in HPV16-positive cells?\",\"answer\":\"ZHPV16E7-GrB inhibited EMT by reducing migration and invasion and modulating EMT markers. It also induced apoptosis through caspase-3/caspase-8 activation and triggered pyroptosis via direct cleavage of GSDME, producing membrane rupture and pro-inflammatory cytokine release.\"}]","Development of ZHPV16E7-granzyme B immunoafﬁtoxin - dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death | PDF",1790190451,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f4faaf475680b730b9f980ea015cfe3.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9a19d36a4ee4295fb22504934b64d35.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a155a2ee298b56f86ac0db5b92d54662.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbb4aedf59fd5ed488c7e129e6644010.webp",980,1385]